| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,266 | 0,273 | 22:21 | |
| 0,266 | 0,284 | 22:00 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19:22 | Cosmos Health erhält dritten Folgeauftrag aus den Vereinigten Arabischen Emiraten | 2 | Investing.com Deutsch | ||
| 19:18 | Cosmos Health receives third UAE order for 60,000 units | 2 | Investing.com | ||
| 19:02 | Cosmos Health Inc.: Cosmos Health Receives Third Consecutive Purchase Order from Pharmalink for 60,000 Units of Sky Premium Life Products in the UAE; Cumulative Orders Reach 270,000 Units, Advancing 5-Year Goal of Over 3 million Units | 281 | ACCESS Newswire | CHICAGO, IL / ACCESS Newswire / April 13, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that... ► Artikel lesen | |
| Fr | Cosmos Health: Nahost-Konflikt ohne wesentliche Auswirkungen - Rekordquartal gemeldet | 1 | Investing.com Deutsch | ||
| Fr | Cosmos Health reports no material impact from Middle East conflict | 2 | Investing.com | ||
| Fr | Cosmos Health sees strong growth, unaffected by Middle East tensions | 7 | Seeking Alpha | ||
| Fr | Cosmos Health Inc.: Cosmos Health Reports No Impact from Iran and Middle East Conflict; Revenue Continues at All-Time High Levels; NOOR U.S. Expansion on Track to Exceed $12 Million Within 12 Months | 314 | ACCESS Newswire | CHICAGO, IL / ACCESS Newswire / April 10, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today confirmed that... ► Artikel lesen | |
| Mi | Cosmos Health plant Markteinführung von Leber-Nahrungsergänzungsmittel in den USA für Q2 2026 | 1 | Investing.com Deutsch | ||
| COSMOS HEALTH Aktie jetzt für 0€ handeln | |||||
| Mi | Cosmos Health plans Q2 U.S. launch of liver supplement Liv18 | 3 | Investing.com | ||
| Mi | Cosmos Health Inc.: Cosmos Health Continues Expansion in the United States with Q2 Launch of Liv18 - a Clinically Proven, Patented Supplement for Liver Fat Reduction | 1.312 | ACCESS Newswire | Powered by BergacynFF, the only patented botanical blend clinically demonstrated to reduce liver fat accumulation and support healthy body weight in two independent randomized controlled trials. CHICAGO... ► Artikel lesen | |
| 01.04. | Cosmos Health's C-Scrub Wash 4% passes European testing standard | 3 | Investing.com | ||
| 01.04. | Cosmos Health: Desinfektionsmittel C-Scrub Wash 4% erfüllt europäische Norm | 5 | Investing.com Deutsch | ||
| 01.04. | Cosmos Health Inc.: Cosmos Health Announces Successful EN 12791 Study Results for C-Scrub Wash 4%, Strengthening Expansion into Hospital and Surgical Markets | 340 | ACCESS Newswire | CHICAGO, IL / ACCESS Newswire / April 1, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that... ► Artikel lesen | |
| 01.04. | Cosmos Health Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 3 | SEC Filings | ||
| 19.03. | Cosmos Health Inc.: Cosmos Health Provides Update; Evaluates Options to Address Valuation Disconnect; Will Issue Updated Guidance Following FY 2025 Results; Record Growth Continues as Significant U.S. Expansion Underway, with Additional $12M+ in High-Marg | 1.482 | GlobeNewswire (Europe) | Continues to deliver record revenue and improving operating metricsSignificant expansion in the United States underway, with NOOR and other Sky Premium Life products expected to drive strong profitability
supported... ► Artikel lesen | |
| 19.03. | Cosmos Health plans guidance update following 2025 results | 1 | Investing.com | ||
| 11.03. | Cosmos Health purchases $600,000 in Bitcoin for treasury | 4 | Investing.com | ||
| 11.03. | Cosmos Health Inc.: Cosmos Health Purchases $600,000 of Bitcoin, Expands Digital Asset Holdings to $3,100,000 | 178 | GlobeNewswire (Europe) | CHICAGO, March 11, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the purchase... ► Artikel lesen | |
| 10.03. | Cosmos Health signs letter of intent for Greek pharmacy network | 2 | Investing.com | ||
| 10.03. | Cosmos Health Inc.: Cosmos Health Enters into LOI to Acquire $11,500,000 Pharmacy Distribution Network; Remains on Track to Deliver 2027 Revenue Guidance of $155,800,000 | 317 | GlobeNewswire (Europe) | CHICAGO, Ill., March 10, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 32,240 | +0,55 % | Novo Nordisk: Neue Abnehm-Spritze setzt Maßstäbe | Novo Nordisk bringt mit Wegovy HD eine deutlich stärkere Version seiner Abnehmspritze auf den US-Markt und erzielt beeindruckende klinische Ergebnisse mit bis zu 21 Prozent Gewichtsverlust. Gleichzeitig... ► Artikel lesen | |
| PFIZER | 23,220 | +1,20 % | JPMORGAN stuft PFIZER INC auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Pfizer mit einem Kursziel von 30 US-Dollar auf "Neutral" belassen. Chris Schott sieht für die Ziele des Pharmaherstellers Luft... ► Artikel lesen | |
| NOVARTIS | 131,48 | -0,35 % | UBS stuft NOVARTIS AG auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Novartis mit einem Kursziel von 116 Franken auf "Neutral" belassen. Mit seinen Schätzungen für Umsatz und operatives Ergebnis... ► Artikel lesen | |
| AURORA CANNABIS | 2,950 | +0,41 % | Bioxyne unterzeichnet Herstellungsvereinbarung mit globalem Cannabisführer Aurora Cannabis | Die australische Bioxyne Limited (ASX: BXN) ("Bioxyne" oder "das Unternehmen") freut sich, über ihre hundertprozentige
Tochtergesellschaft Breathe Life Sciences (BLS) bekannt zu geben, dass sie... ► Artikel lesen | |
| SANOFI | 79,56 | -1,11 % | JPMORGAN stuft SANOFI auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Sanofi mit einem Kursziel von 95 Euro auf "Neutral" belassen. Analyst Richard Vosser wertet die Ergebnisse der Phase-II-Studien... ► Artikel lesen | |
| GSK | 24,900 | +0,20 % | JPMORGAN stuft GSK auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für GSK mit einem Kursziel von 1700 Pence auf "Underweight" belassen. Mit Blick auf das erste Quartal liege er mit seinen Umsatzschätzungen... ► Artikel lesen | |
| CANOPY GROWTH | 0,909 | +0,98 % | CANOPY GROWTH CORPORATION: Stabilität als Signal | ||
| STADA ARZNEIMITTEL | - | - | Stada baut interne Kommunikation international aus | ||
| ELI LILLY | 790,80 | -1,29 % | Deutlich höhere Dosis: Wegovy-Offensive: Novo Nordisk kontert Eli Lilly mit Mega-Dosis | © Foto: Christian Schultz/dpaNovo Nordisk geht in die Offensive: Mit einer deutlich höheren Wegovy-Dosis will der Konzern im boomenden Markt für Abnehmmedikamente verlorene Marktanteile zurückholen... ► Artikel lesen | |
| MERCK & CO | 102,44 | -1,06 % | Merck Launches Tender Offer To Acquire Terns Pharmaceuticals | KENILWORTH (NJ) (dpa-AFX) - Merck & Co Inc. (MRK) said Tuesday it has commenced a cash tender offer to acquire all outstanding shares of Terns Pharmaceuticals, Inc. (TERN). The move follows... ► Artikel lesen | |
| TILRAY BRANDS | 5,710 | +1,60 % | Tilray Brands, Inc.: Tilray Expands Canadian Cannabis Portfolio with Launch of PORTAL, A New High Intensity Brand for the Experienced Consumer | TORONTO, April 08, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. company (Nasdaq: TLRY; TSX: TLRY) a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis... ► Artikel lesen | |
| TEVA | 26,200 | -0,38 % | Teva Pharmaceutical Industries Limited (TEVA): Billionaire Stan Druckenmiller Trims Position | ||
| VERTEX PHARMACEUTICALS | 373,25 | +0,30 % | Vertex Licenses Halozyme's Hypercon Technology For Use In Up To Three Drug Targets | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Halozyme Therapeutics (HALO) announced its subsidiary, Halozyme Hypercon, entered into a global exclusive collaboration and license agreement with Vertex... ► Artikel lesen | |
| INNOCAN PHARMA | 3,750 | -6,95 % | Innocan Pharma Corporation: Innocan Pharma Announces Closing of Additional Debenture | The Debenture will bear interest at the rate of 10% per annum and matures at the earlier of: (i) 12 months from the date of issuance; and (ii) the completion of the Company's previously announced proposed... ► Artikel lesen | |
| ABBOTT LABORATORIES | 85,62 | +0,14 % | TD Cowen reiterates Buy on Abbott Labs stock, cites Cologuard strength |